SAN DIEGO—(BUSINESS WIRE)—Aug. 24, 2016—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system (CNS)
disorders, today announced the appointment of Todd S. Young as Executive
Vice President, Chief Financial Officer, effective August 22, 2016. Mr.
Young reports to Steve Davis, ACADIA’s President and Chief Executive
Officer.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20160824005294/en/
Todd S. Young, Executive Vice President, Chief Financial Officer of ACADIA Pharmaceuticals (Photo: Business Wire)
“Todd is a seasoned leader with significant financial and operational
experience in the biopharmaceutical industry,” said Steve Davis. “His
proven finance and leadership skills will be key as we bring NUPLAZID™
(pimavanserin) to patients in need, seek to maximize the significant
opportunities ahead for pimavanserin, and deliver on our vision of
building a leading CNS company. We welcome Todd to our team and look
forward to his contributions.”
Mr. Young joins ACADIA from Baxalta Incorporated, where he served as
Senior Vice President and Treasurer and played an integral role as a
business leader and in creating the initial capital structure of
Baxalta. Baxalta was acquired by Shire in June 2016. Prior to the
acquisition, Baxalta was a global biopharmaceutical company with $6
billion in revenue that was formed in July 2015 when Baxter
International Inc. spun-out its biopharmaceutical division. Prior to
Baxalta, Mr. Young worked for over 14 years at Baxter holding multiple
leadership roles, including Corporate Vice President and Treasurer, Vice
President, International Finance, and Vice President, Global Financial
Planning and Analysis (FP&A). Mr. Young’s global FP&A team was
responsible for driving Baxter’s budgeting, forecasting, and long-range
financial planning. As finance leader for Baxter’s international
operations, he led a team of 900 finance members and helped drive
business results and strategic decision making for the company’s $8
billion international commercial operations.
Early in his career, Mr. Young practiced as a tax attorney at a major
law firm. Mr. Young earned his Bachelor of Arts degree in Economics from
Grinnell College and his Juris Doctor from the University of Michigan
School of Law.
“I am thrilled to join ACADIA,” said Todd Young. “With the recent
commercial launch of NUPLAZID, the company has entered an exciting new
phase. I look forward to executing on ACADIA’s growth strategy and
building long-term value for shareholders.”
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development and
commercialization of innovative medicines to address unmet medical needs
in central nervous system disorders. ACADIA maintains a website at www.acadia-pharm.com
to which we regularly post copies of our press releases as well as
additional information and through which interested parties can
subscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements include but are
not limited to statements related to ACADIA’s plans to bring NUPLAZID™
(pimavanserin) to patients in need, to maximize opportunities for
pimavanserin, and to build a leading CNS company and shareholder value,
as well as potential contributions of Mr. Young as ACADIA’s Executive
Vice President, Chief Financial Officer. These statements are only
predictions based on current information and expectations and involve a
number of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to various
factors, including the risks and uncertainties inherent in drug
discovery, development, approval and commercialization, and in
collaborations with others, and the fact that past results of clinical
trials may not be indicative of future trial results. For a discussion
of these and other factors, please refer to ACADIA’s annual report on
Form 10-K for the year ended December 31, 2015 as well as ACADIA’s
subsequent filings with the Securities and Exchange Commission. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. This caution is made
under the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. All forward-looking statements are qualified in
their entirety by this cautionary statement and ACADIA undertakes no
obligation to revise or update this press release to reflect events or
circumstances after the date hereof, except as required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160824005294/en/
Source: ACADIA Pharmaceuticals Inc.
Investor Contact:
ACADIA Pharmaceuticals Inc.
Lisa
Barthelemy, Investor Relations
(858) 558-2871
[email protected]
or
Media
Contact:
Taft and Partners
Ted Deutsch
(609)
578-8765
[email protected]